A Pivotal April for Bayer: Legal and Operational Crossroads

Bayer faces a pivotal month with its AGM, a key Supreme Court hearing on Roundup, and new drug approvals. The outcomes will define its legal and financial future.

April presents a series of critical events for the Leverkusen-based pharmaceutical and agricultural giant, Bayer. The coming weeks will see the company's operational present collide with its legal past, setting the stage for its future trajectory. As shareholders prepare to accept a nominal dividend, the financial markets are intently focused on developments in Washington D.C.

The immediate focus is a virtual Annual General Meeting scheduled for April 24. Shareholders will vote on a proposed dividend of just €0.11 per share, a symbolic figure that underscores the severe financial impact of ongoing litigation. In the previous year, special provisions for legal disputes pushed the company into a net loss exceeding €3.6 billion. Despite this historical burden, Bayer's stock has demonstrated notable resilience, currently trading at €38.88 and marking a substantial 76 percent gain over the past twelve months.

Operational Advances Provide Counterbalance

Away from the courtroom, Bayer's pharmaceuticals division has secured tangible progress. Japanese health authorities recently granted two significant approvals, a notable achievement given Japan's status as one of the world's most stringent reference markets. The approvals cover Eylea 8 mg for specific retinal conditions and a novel MRI contrast agent called Ambelvist. These successes are expected to strengthen the company's position in ongoing approval processes in key regions like the United States, the European Union, and China.

The Supreme Court Showdown

Merely three days after the shareholder meeting, attention will shift to the United States Supreme Court. On April 27, oral arguments begin in a landmark case concerning alleged cancer risks associated with the weedkiller Roundup.

The core legal question is whether federal guidelines from the U.S. Environmental Protection Agency (EPA)—which do not mandate cancer warnings on glyphosate-based products—can preempt state-level lawsuits. The U.S. Department of Justice has formally backed Bayer's legal position in the matter. A ruling in the company's favor, expected in the latter half of June, could dramatically reduce the single largest legal risk in Bayer's history. Conversely, an unfavorable decision would jeopardize the existing settlement strategy, which currently allocates approximately €5 billion for payouts through 2026.

A Packed Agenda of Key Dates

The strategic path for Bayer will be shaped by a dense calendar of events in the near term:

• April 24: Virtual Annual General Meeting.
• April 27: Ex-dividend date and commencement of U.S. Supreme Court hearings.
• May 12: Publication of first-quarter (Q1) financial results.
• June 4: Deadline for the opt-out period in the multi-billion euro glyphosate settlement.

This confluence of operational milestones and high-stakes legal proceedings makes April a definitive month for the company, as it seeks to navigate past liabilities while building future growth.